title: Recent advances in the pharmacologic management of diabetes mellitus.
abstract: The importance of glucose control in reducing the complications of diabetes mellitus has been clearly demonstrated. The emergency physician routinely is expected to treat a wide range of problems related to this disease, including making the initial diagnosis of type 2 and occasionally type 1 diabetes. Also common are patients with poorly controlled diabetes. The recent introduction of new classes of agents to lower blood glucose, especially in type 2 diabetes, should improve the control in this category of patient and reduce the complication rate. Some of these agents, such as troglitazone, have potentially fatal complications and require careful monitoring. Emergency physicians should be aware of the common complications of these drugs because patients can present to the ED with them. Hypoglycemia, a common cause of 911 calls and emergency visits, is not a side effect of either metformin or acarbose. Insulin lispro has improved postprandial glycemic control for type 1 and some insulin-requiring type 2 diabetics. Hypoglycemia is less of a risk with insulin lispro, and quality of life is better with this rapidly acting insulin. Newer methods of insulin delivery, such as continuous subcutaneous infusion, have greatly improved glucose control, given greater freedom to patients, and reduced the risks of hypoglycemia.
authors.affiliation: Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA. fcarlton@pol.net
authors.forename: F B
authors.initials: FB
authors.lastname: Carlton
mesh_terms: D020909:Acarbose / Q000009:adverse effects / Q000627:therapeutic use; D000284:Administration, Oral; D002219:Carbamates / Q000627:therapeutic use; D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D062787:Drug Overdose; D004630:Emergencies; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D061268:Insulin Lispro; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
chemical_list: D002219:Carbamates; D002839:Chromans; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D010880:Piperidines; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; C072379:repaglinide; D008687:Metformin; D000077288:Troglitazone; D020909:Acarbose